account_balance
Investment manager · 13F filer · SEC CIK 1637946
General Catalyst Group Management, LLC
Reported value$189Mas of Jun 30, 2026
Positions14 4 new, 2 sold out
Top 10 weight99.0%AVBP alone is 28%
FiledAug 1748 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
AVBPArriVent BioPharma, Inc.
27.5%
PBLSParabilis Medicines, Inc.
23.2%New
CARTMaplebear Inc.
17.9%
MAZEMaze Therapeutics, Inc.
16.4%
ODTXOdyssey Therapeutics, Inc.
8.0%New
EIKN2.1%GUTS2.1%LIFE0.7%AVBPArriVent BioPharma, Inc.
27.5%
PBLSParabilis Medicines, Inc.
23.2%New
CARTMaplebear Inc.
17.9%
MAZEMaze Therapeutics, Inc.
16.4%
ODTXOdyssey Therapeutics, Inc.
8.0%New
Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
AVBP ArriVent BioPharma, Inc. 27.5% HeldPBLS Parabilis Medicines, Inc. 23.2% NewCART Maplebear Inc. 17.9% HeldMAZE Maze Therapeutics, Inc. 16.4% HeldODTX Odyssey Therapeutics, Inc. 8.0% NewEIKN Eikon Therapeutics, Inc. 2.1% HeldGUTS Fractyl Health, Inc. 2.1% HeldLIFE Ethos Technologies Inc. 0.7% HeldCPNG Coupang, Inc. 0.5% Added +49%AMZN Amazon.com Inc 0.5% Added +50%META Meta Platforms, Inc. 0.4% Added +101%DASH DoorDash, Inc. 0.3% New
What changed
Biggest moves since Mar 31, 2026
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.